{"entity":{"id":"d3-bio-wuxi","kind":"company","name":"D3 Bio (Wuxi)","aka":["D3 Bio (Wuxi) Co., Ltd"],"tldr":"D3 Bio (Wuxi) is a China-based biotechnology company running 2 late-stage cancer trials.","summary":"D3 Bio (Wuxi), based in Wuxi, China, is a biotechnology company. D3 Bio is a private, clinical-stage biotechnology company developing precision oncology and immunology medicines targeting immune pathways and tumour-driving mutations. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials. The largest, NCT05410145 (A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumours With a KRAS p.G12C Mutation), plans to enrol 442 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website. Its website describes D3S-001 as a next-generation KRAS G12C-selective inhibitor for non-small-cell lung and colorectal cancers with that mutation, and D3S-003 as a KRAS G12D inhibitor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.d3bio.com"},{"label":"ClinicalTrials.gov: trials led by D3 Bio (Wuxi)","url":"https://clinicaltrials.gov/search?lead=D3%20Bio%20(Wuxi)%20Co.%2C%20Ltd"},{"label":"D3 Bio pipeline","url":"https://www.d3bio.com/"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","colorectal"],"sections":[],"technologies":["kras-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct05886920","nct05410145"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Wuxi","country":"CN","companyType":"biotech","website":"https://www.d3bio.com","founded":2020,"stage":"growth","investors":[],"funding":[]},"route":"/companies/d3-bio-wuxi/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}],"trial":[{"id":"nct05886920","kind":"trial","name":"A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations","route":"/trials/nct05886920/"},{"id":"nct05410145","kind":"trial","name":"A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation","route":"/trials/nct05410145/"}]}}